C. Flefleh

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Zheng Yang, David Kan, F. Lee, 2006, Clinical Cancer Research.

Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts.

F. Lee, D. Kan, W. Rose, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model

F. Lee, R. Kramer, T. Wong, 2005, Clinical Cancer Research.

BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo

F. Lee, C. Fairchild, R. Borzilleri, 2005 .

Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels

F. Luo, S. Castaneda, I. Inigo, 2006, Molecular Cancer Therapeutics.

Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668

F. Lee, N. Donato, M. Talpaz, 2004 .

Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.

D. Goldenberg, R. Blumenthal, J. Burton, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

F. Lee, R. Kramer, F. Luo, 2005, Cancer Chemotherapy and Pharmacology.

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

F. Lee, R. Borzilleri, F. Luo, 2004 .

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

F. Lee, R. Borzilleri, L. Lombardo, 2005 .

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.

F. Lee, R. Borzilleri, F. Luo, 2004 .